Literature DB >> 29233531

Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.

Se Ik Kim1, Ji Won Lee2, Maria Lee3, Hee Seung Kim1, Hyun Hoon Chung1, Jae-Weon Kim1, Noh Hyun Park1, Yong-Sang Song1, Jeong-Sun Seo4.   

Abstract

OBJECTIVE: To analyze whole exome sequencing (WES) data on ovarian clear cell carcinoma (OCCC) in Korean patients via the technique of next generation sequencing (NGS). Genomic profiles were compared between endometriosis-associated OCCC (EMS-OCCC) and Non-EMS-OCCC.
METHODS: We used serum samples and cancer tissues, stored at the Seoul National University Hospital Human Biobank, that were initially collected from women diagnosed with OCCC between 2012 and 2016. In total, 15 patients were enrolled: 5 with pathologically confirmed EMS-OCCC and 10 with Non-EMS-OCCC. We performed NGS WES on 15 fresh frozen OCCC tissues and matched serum samples, enabling comprehensive genomic characterization of OCCC.
RESULTS: OCCC was characterized by complex genomic alterations, with a median of 178 exonic mutations (range, 111-25,798) and a median of 343 somatic copy number variations (range, 43-1,820) per tumor sample. In all, 54 somatic mutations were discovered across 14 genes, including PIK3CA (40%), ARID1A (40%), and KRAS (20%) in the 15 Korean OCCCs. Copy number gains in NTRK1 (33%), MYC (40%), and GNAS (47%) and copy number losses in TET2 (73%), TSC1 (67%), BRCA2 (60%), and SMAD4 (47%) were frequent. The significantly altered pathways were associated with proliferation and survival (including the PI3K/AKT, TP53, and ERBB2 pathways) in 87% of OCCCs and with chromatin remodeling in 47% of OCCCs. No significant differences in frequencies of genetic alterations were detected between EMS-OCCC and Non-EMS-OCCC groups.
CONCLUSION: We successfully characterized the genomic landscape of 15 Korean patients with OCCC. We identified potential therapeutic targets for the treatment of this malignancy.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Clear cell carcinoma; Genital neoplasms, female; Ovarian neoplasms; Whole exome sequencing

Mesh:

Substances:

Year:  2017        PMID: 29233531     DOI: 10.1016/j.ygyno.2017.12.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

Review 1.  Precision medicine for ovarian clear cell carcinoma based on gene alterations.

Authors:  Takafumi Kuroda; Takashi Kohno
Journal:  Int J Clin Oncol       Date:  2020-02-04       Impact factor: 3.402

2.  Resibufogenin inhibits ovarian clear cell carcinoma (OCCC) growth in vivo, and migration of OCCC cells in vitro, by down-regulating the PI3K/AKT and actin cytoskeleton signaling pathways.

Authors:  Guannan Zhou; Zhongyi Zhu; Lihua Li; Jingxin Ding
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

3.  Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy.

Authors:  Kosuke Murakami; Yasushi Kotani; Hidekatsu Nakai; Noriomi Matsumura
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

4.  Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).

Authors:  Wei Jiang; Shuang Ye; Libing Xiang; Wentao Yang; Tiancong He; Xuan Pei; Lin Guo; Huijuan Yang
Journal:  J Ovarian Res       Date:  2018-07-09       Impact factor: 4.234

5.  Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.

Authors:  Kazuaki Suda; Luis Antonio Cruz Diaz; Kosuke Yoshihara; Hirofumi Nakaoka; Nozomi Yachida; Teiichi Motoyama; Ituro Inoue; Takayuki Enomoto
Journal:  Cancer Sci       Date:  2020-06-26       Impact factor: 6.716

6.  Identification of potential key genes associated with ovarian clear cell carcinoma.

Authors:  Youzheng Xu; Keng Shen
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

7.  ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer.

Authors:  Ling Wang; Zhuo Yang; Yi Liu; Ya-Nan Wang; Jing-Yi Guo; Qi-Jun Wu; Ting-Ting Gong
Journal:  J Cancer       Date:  2018-10-21       Impact factor: 4.207

8.  Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.

Authors:  Qin Yang; Cancan Zhang; Yuan Ren; Huan Yi; Tianjiao Luo; Fangliang Xing; Xuefeng Bai; Lining Cui; Linyan Zhu; Jun Ouyang; Pengcheng Jiang; Weirong Fan; Jianping Qiu; Fengmian Wang; Xin Xing; Zhigang Zhang; Xueli Zhang; Rong Zhang
Journal:  Neoplasia       Date:  2020-07-07       Impact factor: 5.715

9.  BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea.

Authors:  Do Hoon Kim; Chi Heum Cho; Sun Young Kwon; Nam Hee Ryoo; Dong Seok Jeon; Wonmok Lee; Jung Sook Ha
Journal:  J Gynecol Oncol       Date:  2018-11       Impact factor: 4.401

10.  The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.

Authors:  Hao Wang; Lei Fang; Jing Jiang; Ye Kuang; Beidi Wang; Xiumin Shang; Peilin Han; Yue Li; Meimei Liu; Zongfeng Zhang; Peiling Li
Journal:  Cell Death Dis       Date:  2018-10-30       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.